Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Alaa Ramadan , Mohamed El-Samahy , Amr Elrosasy , Mohammed Al-Tawil , Ahmed Abdelaziz , Mostafa A Soliman , Mohamed Abouzid
{"title":"Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials","authors":"Alaa Ramadan ,&nbsp;Mohamed El-Samahy ,&nbsp;Amr Elrosasy ,&nbsp;Mohammed Al-Tawil ,&nbsp;Ahmed Abdelaziz ,&nbsp;Mostafa A Soliman ,&nbsp;Mohamed Abouzid","doi":"10.1016/j.pupt.2023.102252","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objectives</h3><p><span>Chronic refractory cough is a challenging condition that requires a thorough evaluation and management approach. P2X3 receptors<span> that are ATP-dependent play an important part in nerve fiber sensitization and pathological pain pathways. We conducted this </span></span>systematic review<span> and meta-analysis to determine the long-term safety and efficacy of P2X3 receptor antagonist drugs<span> in chronic cough.</span></span></p></div><div><h3>Methods</h3><p>We systematically searched PubMed, Scopus, Web of Science, and Embase to identify all relevant published studies through January 15, 2023 that assessed P2X3 antagonists in chronic cough. The protocol was registered in the PROSPERO database with ID: CRD42023422408. Efficacy outcomes were awake (daytime) cough frequency, night cough frequency, 24-h cough frequency, Cough Severity Diary, and total Leicester Cough Questionnaire score. We used the random-effect model to pool the data using RStudio and CMA software.</p></div><div><h3>Results</h3><p><span>A total of 11 randomized controlled trials comprising 1350 patients receiving a p2x3 antagonist compared to the placebo group were included in this meta-analysis. A significant decrease in 24-h cough frequency (MD = −4.99, 95% CI [−7.15 to −2.82], P &lt; 0.01), awake (daytime) cough frequency (MD = −7.18, 95% CI [−9.98 to 4.37], P &lt; 0.01), and total Leicester Cough Questionnaire score (MD = 1.74, 95% CI [1.02 to 2.46], P &lt; 0.01) exhibited between the P2X3 antagonist and placebo groups. The frequency of the night cough showed an insignificant difference between the two groups. According to the safety, drug-related adverse events, </span>dysgeusia<span><span>, hypogeusia, and </span>ageusia significantly increased between the P2X3 antagonist and placebo groups.</span></p></div><div><h3>Conclusion</h3><p>P2X3 receptor antagonists are promising drugs for treating chronic cough by significantly reducing the frequency, severity, and quality. Some potential side effects may include drug-related adverse events such as hypogeusia, ageusia, and dysgeusia.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553923000640","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives

Chronic refractory cough is a challenging condition that requires a thorough evaluation and management approach. P2X3 receptors that are ATP-dependent play an important part in nerve fiber sensitization and pathological pain pathways. We conducted this systematic review and meta-analysis to determine the long-term safety and efficacy of P2X3 receptor antagonist drugs in chronic cough.

Methods

We systematically searched PubMed, Scopus, Web of Science, and Embase to identify all relevant published studies through January 15, 2023 that assessed P2X3 antagonists in chronic cough. The protocol was registered in the PROSPERO database with ID: CRD42023422408. Efficacy outcomes were awake (daytime) cough frequency, night cough frequency, 24-h cough frequency, Cough Severity Diary, and total Leicester Cough Questionnaire score. We used the random-effect model to pool the data using RStudio and CMA software.

Results

A total of 11 randomized controlled trials comprising 1350 patients receiving a p2x3 antagonist compared to the placebo group were included in this meta-analysis. A significant decrease in 24-h cough frequency (MD = −4.99, 95% CI [−7.15 to −2.82], P < 0.01), awake (daytime) cough frequency (MD = −7.18, 95% CI [−9.98 to 4.37], P < 0.01), and total Leicester Cough Questionnaire score (MD = 1.74, 95% CI [1.02 to 2.46], P < 0.01) exhibited between the P2X3 antagonist and placebo groups. The frequency of the night cough showed an insignificant difference between the two groups. According to the safety, drug-related adverse events, dysgeusia, hypogeusia, and ageusia significantly increased between the P2X3 antagonist and placebo groups.

Conclusion

P2X3 receptor antagonists are promising drugs for treating chronic cough by significantly reducing the frequency, severity, and quality. Some potential side effects may include drug-related adverse events such as hypogeusia, ageusia, and dysgeusia.

P2X3受体拮抗剂治疗难治性或不明原因慢性咳嗽的安全性和有效性:11项随机对照试验的系统回顾和荟萃分析
背景和目的慢性难治性咳嗽是一种具有挑战性的疾病,需要彻底的评估和管理方法。依赖于ATP的P2X3受体在神经纤维敏化和病理性疼痛途径中发挥重要作用。我们进行了这项系统综述和荟萃分析,以确定P2X3受体拮抗剂药物治疗慢性咳嗽的长期安全性和有效性。方法我们系统地搜索PubMed、Scopus、Web of Science和Embase,以确定截至2023年1月15日所有已发表的评估P2X3拮抗剂治疗慢性咳嗽的相关研究。该协议已在PROSPERO数据库中注册,ID为CRD42023422408。疗效结果为清醒(白天)咳嗽频率、夜间咳嗽频率、24小时咳嗽频率、咳嗽严重程度日记和莱斯特咳嗽问卷总分。我们使用随机效应模型,使用RStudio和CMA软件对数据进行汇总。结果本荟萃分析共纳入11项随机对照试验,包括1350名接受p2x3拮抗剂治疗的患者,与安慰剂组相比。P2X3拮抗剂组和安慰剂组24小时咳嗽频率(MD=−4.99,95%CI[-7.15至−2.82],P<;0.01)、清醒(白天)咳嗽频率(MD=−7.18,95%CI[−9.98至4.37],P<:0.01)和莱斯特咳嗽问卷总分(MD=1.74,95%CI[1.02至2.46],P<!0.01)显著降低。夜间咳嗽的频率在两组之间显示出不显著的差异。根据安全性,P2X3拮抗剂组和安慰剂组的药物相关不良事件、味觉障碍、味觉减退和衰老显著增加。结论P2X3受体拮抗剂可显著降低慢性咳嗽的频率、严重程度和质量,是一种有前景的治疗慢性咳嗽的药物。一些潜在的副作用可能包括与药物相关的不良事件,如味觉减退、衰老和味觉障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
41
审稿时长
42 days
期刊介绍: Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信